Revenue Update on Athersys(NASDAQ:ATHX)

Athersys(NASDAQ:ATHX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $595.00K. Analysts estimated a revenue of $320.00K. Earnings per share were $-0.08. Analysts had estimated an EPS of $-0.10.

Athersys (ATHX) shares turned negative on Wednesdays trading session with the shares closing down -0.03 points or -1.52% at a volume of 1,20,600. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $2.02. The peak price level was also seen at $2.02 while the days lowest was $1.95. Finally the shares closed at $1.95. The 52-week high of the shares is $2.9 while the 52-week low is $0.94. According to the latest information available, the market cap of the company is $166 M.

Several Insider Transactions has been reported to the SEC. On Jun 21, 2016, William Jr Lehmann (President and COO) sold 25,000 shares at $2.17 per share price.Also, On Sep 21, 2015, John J Harrington (Exec Vice Pres and CSO) sold 8,150 shares at $1.36 per share price.On Sep 21, 2015, Bokkelen Gil Van (Chairman and CEO) sold 9,500 shares at $1.36 per share price, according to the Form-4 filing with the securities and exchange commission.

Athersys Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy is being evaluated in multiple clinical trials. Its current clinical development programs are focused on treating inflammatory and immune disorders neurological conditions cardiovascular disease and other conditions. It is also identifying and developing small molecule compounds with applications in indications such as obesity related metabolic conditions and neurological conditions. It is engaged in the preparation stages for clinical studies in other targeted areas including the treatment of ARDS. Its current programs include Ischemic Stroke Acute Myocardial Infarction Acute Respiratory Distress Syndrome Hematopoietic Stem Cell Transplant/GvHD and Inflammatory Bowel Disease. In addition to the programs it is also conducting or supporting clinical activity in other areas such as solid organ transplant.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Athersys - Is it time to Sell?

Top Brokerage Firms are advising their investors on Athersys. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.